About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Lipoprotein(a) – does it matter when LDL cholesterol is low?
Lipoprotein(a) is now recognised as an independent risk factor for cardiovascualr disease.
But is it also relevant to consider lipoprotein(a) when LDL cholesterol is low?
Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the evidence.
Hot Topics
Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel
Clinical trials have clearly proven the efficacy and short-term safety of statin treatment. But, with people taking these medications lifelong, are there any adverse effects to consider in the longer-term? This new statement weighs the evidence versus the perception of risk.
Video: EAS Consensus Panel: Statins do not impair cognitive function
Watch the video
Report: Neurocognitive effects and PCSK9 inhibition
Read the report
From the Editors
The lipoprotein(a) – LDL cholesterol conundrumProfessor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses issues related to lowering elevated lipoprotein(a): is it beneficial when LDL cholesterol is low?
Lowering lipoprotein(a) when LDL-C is very low
Watch the videoLowering lipoprotein(a) for clinical benefit
Watch the videoHow much lipoprotein(a) lowering for CV benefit?
Read the reportLatest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
